
Emily A Blumberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4882024/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. Clinical Infectious Diseases, 2024, 78, 711-718.	2.9	6
2	Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research. American Journal of Transplantation, 2022, 22, 24-27.	2.6	8
3	National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases, 2022, 74, 2010-2019.	2.9	7
4	Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. American Journal of Transplantation, 2022, 22, 279-288.	2.6	63
5	Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. American Journal of Transplantation, 2022, 22, 599-609.	2.6	12
6	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transplant Infectious Disease, 2022, 24, e13770.	0.7	3
7	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney International Reports, 2022, 7, 241-250.	0.4	12
8	Impact of donor multidrugâ€resistant organisms on solid organ transplant recipient outcomes. Transplant Infectious Disease, 2022, 24, e13783.	0.7	17
9	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 690-701.	2.9	97
10	Active Tuberculosis After Solid Organ Transplantation in Individuals With Negative Pretransplant QuantiFERON-TB Gold Testing: A Case Series. Transplantation Proceedings, 2022, 54, 610-614.	0.3	2
11	What is the optimal antimicrobial prophylaxis to prevent postoperative infectious complications after liver transplantation? A systematic review of the literature and expert panel recommendations. Clinical Transplantation, 2022, 36, e14631.	0.8	14
12	Photo Quiz: A 52-Year-Old Liver Transplant Patient with Chronic Diarrhea. Journal of Clinical Microbiology, 2022, 60, e0097621.	1.8	1
13	Answer to March 2022 Photo Quiz. Journal of Clinical Microbiology, 2022, 60, e0098021.	1.8	0
14	Critically important outcomes for infection in trials in kidney transplantation: An international survey of patients, caregivers, and health professionals. Clinical Transplantation, 2022, 36, e14660.	0.8	2
15	A phase I trial of cyclosporine for hospitalized patients with COVID-19. JCI Insight, 2022, 7, .	2.3	8
16	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clinical Infectious Diseases, 2021, 73, e4090-e4099.	2.9	332
17	Risk Factors for Extended-Spectrum β-lactamase–Producing Enterobacterales Bloodstream Infection Among Solid-Organ Transplant Recipients. Clinical Infectious Diseases, 2021, 72, 953-960.	2.9	22
18	Ten years of donor-derived disease: A report of the disease transmission advisory committee. American Journal of Transplantation, 2021, 21, 689-702.	2.6	70

EMILY A BLUMBERG

#	Article	IF	CITATIONS
19	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant. American Journal of Transplantation, 2021, 21, 1780-1788.	2.6	14
20	Impact of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 925-937.	2.6	98
21	Impact of preâ€transplant carbapenemâ€resistant <i>Enterobacterales</i> colonization and/or infection on solid organ transplant outcomes. Clinical Transplantation, 2021, 35, e14239.	0.8	17
22	Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review. Transplantation, 2021, 105, 2632-2638.	0.5	4
23	Clinical prediction tool for extendedâ€spectrum betaâ€lactamaseâ€producing enterobacterales as the etiology of a bloodstream infection in solid organ transplant recipients. Transplant Infectious Disease, 2021, 23, e13599.	0.7	5
24	SARS-CoV-2 Vaccination and Solid Organ Transplant Patients. Transplantation, 2021, Publish Ahead of Print, e131-e132.	0.5	3
25	Should Health Care Institutions Mandate SARS-CoV-2 Vaccination for Staff?. Open Forum Infectious Diseases, 2021, 8, ofab155.	0.4	4
26	The future of SARSâ€CoVâ€2 vaccines in transplant recipients: To be determined. American Journal of Transplantation, 2021, 21, 2629-2630.	2.6	6
27	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circulation: Heart Failure, 2021, 14, e007957.	1.6	24
28	Antibiotic Utilization in Deceased Organ Donors. Clinical Infectious Diseases, 2021, 73, 1284-1287.	2.9	4
29	Granulomatous Dermatitis Associated With Rubella Virus Infection in an Adult With Immunodeficiency. JAMA Dermatology, 2021, 157, 842.	2.0	14
30	COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. American Journal of Transplantation, 2021, 21, 2774-2784.	2.6	37
31	A pragmatic outreach pilot to understand and overcome barriers to COVIDâ€19 vaccination in abdominal organ transplant. Transplant Infectious Disease, 2021, 23, e13722.	0.7	10
32	The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy. American Journal of Transplantation, 2021, 21, 2637-2645.	2.6	26
33	Healthcare resource use among solid organ transplant recipients hospitalized with COVIDâ€19. Clinical Transplantation, 2021, 35, e14174.	0.8	3
34	949. Risk Factors for Subsequent Multidrug-Resistant Gram-Negative Bloodstream Infection Following an Initial Gram-Negative Bloodstream Infection among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, S567-S568.	0.4	0
35	1385. Impact of Deceased Organ Donor Injection Drug Use on Donor Culture Positivity. Open Forum Infectious Diseases, 2021, 8, S778-S778.	0.4	0
36	Clarifying the HOPE Act landscape: The challenge of donors with falseâ€positive HIV results. American Journal of Transplantation, 2020, 20, 617-619.	2.6	13

EMILY A BLUMBERG

#	Article	IF	CITATIONS
37	HIV and organ transplantation. Current Opinion in Organ Transplantation, 2020, 25, 371-376.	0.8	2
38	Response to letters concerning: "Kidney transplantation and donation in the transgender population: A singleâ€institution case seriesâ€i American Journal of Transplantation, 2020, 20, 3695-3696.	2.6	0
39	Kidney transplantation and donation in the transgender population: A single-institution case series. American Journal of Transplantation, 2020, 20, 2899-2904.	2.6	18
40	The Struggling Infectious Diseases Fellow: Remediation Challenges and Opportunities. Open Forum Infectious Diseases, 2020, 7, ofaa058.	0.4	5
41	Impact of deceased donor multidrug-resistant bacterial organisms on organ utilization. American Journal of Transplantation, 2020, 20, 2559-2566.	2.6	14
42	Coronavirus disease 2019: Implications of emerging infections for transplantation. American Journal of Transplantation, 2020, 20, 1768-1772.	2.6	149
43	Guidance for evaluating and testing patients for COVIDâ€19. American Journal of Transplantation, 2020, 20, 1457-1457.	2.6	0
44	Foreword: 4th edition of the American Society of Transplantation Infectious Diseases Guidelines. Clinical Transplantation, 2019, 33, e13642.	0.8	16
45	Risk factors for multidrugâ€resistant organisms among deceased organ donors. American Journal of Transplantation, 2019, 19, 2468-2478.	2.6	24
46	Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ. American Journal of Transplantation, 2019, 19, 2525-2532.	2.6	11
47	Organs from Hepatitis C Virus–Positive Donors. New England Journal of Medicine, 2019, 380, 1669-1670.	13.9	15
48	Characterization of early hepatic injury in HCVâ€negative recipients of HCVâ€infected kidneys. Clinical Transplantation, 2019, 33, e13494.	0.8	4
49	Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single-arm trial. American Journal of Transplantation, 2019, 19, 2533-2542.	2.6	88
50	Solid organ transplantation in the HIVâ€infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13499.	0.8	62
51	National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. Journal of the American Society of Nephrology: JASN, 2019, 30, 1939-1951.	3.0	67
52	New treatments for cytomegalovirus in transplant patients. Current Opinion in Nephrology and Hypertension, 2019, 28, 587-592.	1.0	2
53	Cytokine Profiles and Severity of Influenza Infection in Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 535-539.	1.9	3
54	A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 1322-1329.	2.9	145

EMILY A BLUMBERG

#	Article	IF	CITATIONS
55	Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation, 2018, 102, e163-e170.	0.5	35
56	Perioperative Antibiotic Prophylaxis to Prevent Surgical Site Infections in Solid Organ Transplantation. Transplantation, 2018, 102, 21-34.	0.5	80
57	Infectious Complications in Pancreas Transplantation. Current Transplantation Reports, 2018, 5, 289-294.	0.9	2
58	1588. Clinical Prediction Tool for Extended-Spectrum Î' Lactamase-Producing Enterobacteriaceae as the Etiology of Bacteremia in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S497-S497.	0.4	1
59	MMWR: Prevention and control of seasonal influenza. American Journal of Transplantation, 2018, 18, 2829-2829.	2.6	1
60	Twelve-Month Outcomes After Transplant of Hepatitis C–Infected Kidneys Into Uninfected Recipients. Annals of Internal Medicine, 2018, 169, 273-281.	2.0	193
61	Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices: A summary of the MMWR report. American Journal of Transplantation, 2018, 18, 1285-1286.	2.6	3
62	Endocrine and Metabolic Aspects of Tuberculosis. Microbiology Spectrum, 2017, 5, .	1.2	22
63	Bacteremia caused by the photosynthetic environmental bacterium Rhodopseudomonas. Journal of Infection and Chemotherapy, 2017, 23, 720-723.	0.8	4
64	Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. New England Journal of Medicine, 2017, 376, 2394-2395.	13.9	315
65	Hemophilia Liver Transplantation Observational Study. Liver Transplantation, 2017, 23, 762-768.	1.3	13
66	Cryptococcal cellulitis in a heart transplant recipient. JAAD Case Reports, 2016, 2, 403-405.	0.4	1
67	Human Immunodeficiency Virus in Kidney Transplantation. Seminars in Nephrology, 2016, 36, 405-416.	0.6	10
68	Transplantation of Center for Disease Control "High-Risk―Donor Hearts Does Not Adversely Impact Long-Term Outcomes in Adults. Journal of Cardiac Failure, 2016, 22, 376-382.	0.7	20
69	Outcomes Among Children Who Received a Kidney Transplant in the United States From a Hepatitis B Core Antibody–Positive Donor, 1995–2010. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 439-445.	0.6	6
70	Transplantation of "high-risk―donor hearts: Implications for infection. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 213-220.	0.4	35
71	CDC Health Advisory Regarding the Potential for Circulation of Drifted Influenza A (H3N2) Viruses. American Journal of Transplantation, 2015, 15, 568-568.	2.6	0
72	Superior outcomes in HIV–positive kidney transplant patients compared with HCV–infected or HIV/HCV–coinfected recipients. Kidney International, 2015, 88, 341-349.	2.6	57

Emily A Blumberg

#	Article	IF	CITATIONS
73	Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. Clinical Infectious Diseases, 2015, 61, 1054-1062.	2.9	28
74	Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. Aids, 2015, 30, 1.	1.0	47
75	Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States. Transplantation, 2010, 90, 1420-1426.	0.5	27
76	MELD Score Is an Important Predictor of Pretransplantation Mortality in HIV-Infected Liver Transplant Candidates. Gastroenterology, 2010, 138, 159-164.	0.6	77
77	Outcomes of Kidney Transplantation in HIV-Infected Recipients. New England Journal of Medicine, 2010, 363, 2004-2014.	13.9	493
78	Endocrine and Metabolic Aspects of Tuberculosis. , 0, , 515-527.		1